To Enter Herceptin's Market, Wyeth Pursues Aggressive Neratinib Strategy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Three simultaneous Phase III trials may seem like overkill in oncology, but for Wyeth's pan-ErbB inhibitor neratinib, it's a well-constructed effort that could enable the drug to reach the breast cancer market quickly, with a fully developed competitive profile